Gilead Sciences changed its process for requesting the investigational antiviral remdesivir amid a surge in demand among physicians seeking to repurpose the drug as a potential therapy for COVID-19. It is the top story in infectious disease.
Another top story is about the launch of a phase 1 clinical trial for an investigational COVID-19 vaccine, mRNA-1273.
Read these and more popular stories about COVID-19 below:
Gilead revises access to remdesivir for COVID-19 amid surge in demand
Gilead Sciences said it cannot accept new compassionate use requests for its investigational antiviral remdesivir due to “overwhelming demand” from physicians hoping to repurpose the drug as a potential therapy for patients with COVID-19, but there are still ways to get access to the medication. Read more.
Clinical trial of COVID-19 vaccine begins
A phase 1 clinical trial to assess an investigational vaccine for COVID-19 has begun at Kaiser Permanente Washington Health Research Institute in Seattle, according to an NIH news release. Read more.
A phase 1 clinical trial to assess an investigational vaccine for COVID-19 has begun at Kaiser Permanente Washington Health Research Institute in Seattle, according to an NIH news release.
Source: Adobe Stock
IDSA recommends four-tiered approach for COVID-19 testing
The Infectious Diseases Society of America has released recommendations for health care professionals to use in prioritizing testing for COVID-19 during the ongoing shortage of accessible tests. Read more.
Approved HIV treatment offers no benefit for adults with COVID-19
Treatment with lopinavir-ritonavir, a combination treatment for HIV, did not significantly advance the time to clinical improvement, decrease mortality or lower the detectable level of throat viral RNA among patients with serious cases of COVID-19, according to data from a recent study in The New England Journal of Medicine. Read more.
Home assessment team accurately identifies COVID-19, reduces health system exposure
Home assessment teams for patients who need to be evaluated for COVID-19 but do not require hospitalization or emergency medical care may provide useful real-time clinical information about potentially infected individuals, according to a recent study published in Clinical Infectious Diseases. Read more.